Jubilant Pharmova Limited (JUBLPHARMA) Stock Statistics & Valuation Metrics

Jubilant Pharmova Limited has a market cap or net worth of ₹175.87B. The enterprise value is ₹203.20B.

Jubilant Pharmova Limited has 159,281,140 shares outstanding. The number of shares has decreased by -2.65% in one year.

Jubilant Pharmova Limited’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is 20.67%.

The current PE Ratio of Jubilant Pharmova Limited is 38.0. Jubilant Pharmova Limited’s PEG ratio is ―.

In the last 12 months, Jubilant Pharmova Limited had revenue of 72.34B and earned 8.39B in profits. Earnings per share was 52.99.

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.

Jubilant Pharmova Limited pays an annual dividend of ₹5, resulting in a dividend yield of 0.45%

Jubilant Pharmova Limited upcoming earnings date is Oct 17, 2025, TBA (Confirmed).

Jubilant Pharmova Limited as a current ratio of 1.65, with Debt / Equity ratio of 43.66%

In the past 12 months, Jubilant Pharmova Limited has paid 1.44B in taxes.

Jubilant Pharmova Limited EV to EBITDA ratio is 13.81, with an EV/FCF ratio of -372.57.

Jubilant Pharmova Limited has ₹10.89B in cash and marketable securities with ₹27.31B in debt, giving a net cash position of ₹16.42B billion.

Gross margin is 58.92%, with operating margin of 36.62%, and net profit margin of 11.60%.

The average price target for Jubilant Pharmova Limited is ₹1,385.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy